GTX INC Uncategorized Contracts & Agreements

35 Contracts & Agreements
Recent Contracts
Category
Company
Industry
Jur. Jurisdiction
Filed
Description of Securities of the Registrant
GTX INC
Biotechnology
2024
Amendment No. 2 to the Inducement Plan dated December 15, 2021
GTX INC
Biotechnology
2022
Description of Securities of the Registrant
GTX INC
Biotechnology
2022
Open Market Sale Agreement
GTX INC
Biotechnology
NY
2021
First Amendment to Contingent Value Rights Agreement dated November 1, 2021 by and between the Registrant, Marc S. Hanover, as the Holders Representative, and Computershare Inc.,...
GTX INC
Biotechnology
DE
2021
Open Market Sale Agreement
GTX INC
Biotechnology
NY
2021
Engagement Letter between the Registrant and H.C. Wainwright & Co., LLC, dated as of December 9, 2020
GTX INC
Biotechnology
NY
2021
Engagement Letter between Oncternal Therapeutics, Inc. and H.C. Wainwright & Co., LLC, dated as of May 15, 2020
GTX INC
Biotechnology
NY
2020
Description of Securities of Oncternal Therapeutics, Inc
GTX INC
Biotechnology
2020
Research agreement between Oncternal Therapeutics, Inc. and the Regents of the University of California, on behalf of its San Diego Campus, dated November 3, 2016
GTX INC
Biotechnology
CA
2019
Form of Lock-Up Agreement, dated March 6, 2019, by each of the parties named in each agreement therein
GTX INC
Biotechnology
2019
GTx, INC. 175 TOYOTA PLAZA, 7THFLOOR MEMPHIS, TN 38103
GTX INC
Biotechnology
TN
2013
GTx, INC. 175 TOYOTA PLAZA, 7THFLOOR MEMPHIS, TN 38103
GTX INC
Biotechnology
TN
2013
EX-101 INSTANCE DOCUMENT
GTX INC
Biotechnology
2011
GTx, Inc.
GTX INC
Biotechnology
NY
2011
FINANCIAL STATEMENTS
GTX INC
Biotechnology
2011
FINANCIAL STATEMENTS
GTX INC
Biotechnology
2011
FINANCIAL STATEMENTS
GTX INC
Biotechnology
2011
Exhibit No
GTX INC
Biotechnology
NY
2010
FINANCIAL STATEMENTS
GTX INC
Biotechnology
2010
GTx, Inc.
GTX INC
Biotechnology
DE
2008
Exhibit No
GTX INC
Biotechnology
DE
2007
FINANCIAL STATEMENTS
GTX INC
Biotechnology
TN
2007
FINANCIAL STATEMENTS
GTX INC
Biotechnology
TN
2007
FINANCIAL STATEMENTS
GTX INC
Biotechnology
TN
2007
EX-10.34 AMENDMENT DATED JUNE 30, 2006
GTX INC
Biotechnology
2006
EX-10.33 AMENDMENT DATED MAY 23, 2006
GTX INC
Biotechnology
2006
Exhibit No
GTX INC
Biotechnology
NY
2005
Prostarine for the treatment of a benign prostate enlargement that results in obstruction of the urinary tract
GTX INC
Biotechnology
2004
Prostarine for the treatment of a benign prostate enlargement that results in obstruction of the urinary tract
GTX INC
Biotechnology
MO
2004
Prostarine for the treatment of a benign prostate enlargement that results in obstruction of the urinary tract
GTX INC
Biotechnology
DE
2004
Prostarine for the treatment of a benign prostate enlargement that results in obstruction of the urinary tract
GTX INC
Biotechnology
DE
2004
Prostarine for the treatment of a benign prostate enlargement that results in obstruction of the urinary tract
GTX INC
Biotechnology
TN
2004
Prostarine for the treatment of a benign prostate enlargement that results in obstruction of the urinary tract
GTX INC
Biotechnology
DE
2003
Prostarine for the treatment of a benign prostate enlargement that results in obstruction of the urinary tract
GTX INC
Biotechnology
2003